Livafin O 200mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to fungal cell death. This medication is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Livafin O 200mg Capsule is administered orally and is well-absorbed, with bioavailability enhanced when taken with food. The dosage and duration of therapy depend on the type and severity of the infection, as well as patient-specific factors. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea, as well as headache and dizziness. Caution is advised in patients with hepatic impairment, and liver function tests should be monitored during prolonged therapy. Livafin O 200mg Capsule may interact with several drugs metabolized via the cytochrome P450 system, necessitating careful review of concomitant medications. It is contraindicated in patients with known hypersensitivity to Itraconazole and in those receiving certain medications such as cisapride or terfenadine. Proper adherence to prescribed dosing is essential to ensure therapeutic efficacy and minimize resistance.